Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia

American Journal of Medical Genetics, Part A

Volumn 158 A, Issue 10, 2012, Pages 2407-2411

  Kraoua, Lilia ^a   Journel, Hubert ^b   Bonnet, Philippe ^b,c   Amiel, Jeanne ^d   Pouvreau, Nathalie ^a   Baumann, Clarisse ^a   Verloes, Alain ^a   Cavé, Hélène ^a,e  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b Regional Hospital P Chubert   (France)

^c Cayenne Regional Hospital   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e INSERM   (France)

Author keywords

JMML; Noonan syndrome; NRAS; RASopathies

Indexed keywords

DNA;

ADOLESCENT; ADULT; ARTICLE; BRAF GENE; CHILD; FEMALE; FRANCE; GENE; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN CELL; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MEK1 GENE; MEK2 GENE; MUTATIONAL ANALYSIS; NOONAN SYNDROME; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; ONCOGENE N RAS; PRESCHOOL CHILD; PRIORITY JOURNAL; PTPN11 GENE; RAF1 GENE; SHOC2 GENE; SOS1 GENE;

ADOLESCENT; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; GERM-LINE MUTATION; HUMANS; INFANT; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; NOONAN SYNDROME;

EID: 84866511834     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.35513     Document Type: Article

References (20)

1. Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, Digilio C, Palleschi A, Pizzuti A, Grammatico P, Zampino G, Dallapiccola B, Gelb BD, Tartaglia M. 2006. Germline missense mutations affecting KRAS isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 79: 129-135.
2. Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-Zahradnik T, Konig R, Kratz CP, Pantaleoni F, Dentici ML, Joshi VA, Kucherlapati RS, Mazzanti L, Mundlos S, Patton MA, Silengo MC, Rossi C, Zampino G, Digilio C, Stuppia L, Seemanova E, Pennacchio LA, Gelb BD, Dallapiccola B, Wittinghofer A, Ahmadian MR, Tartaglia M, Zenker M. 2010. A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet 42: 27-29.
3. Cordeddu V, Di Schiavi E, Pennacchio LA, Ma'ayan A, Sarkozy A, Fodale V, Cecchetti S, Cardinale A, Martin J, Schackwitz W, Lipzen A, Zampino G, Mazzanti L, Digilio MC, Martinelli S, Flex E, Lepri F, Bartholdi D, Kutsche K, Ferrero GB, Anichini C, Selicorni A, Rossi C, Tenconi R, Zenker M, Merlo D, Dallapiccola B, Iyengar R, Bazzicalupo P, Gelb BD, Tartaglia M. 2009. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet 41: 1022-1026.
4. De Filippi P, Zecca M, Lisini D, Rosti V, Cagioni C, Carlo-Stella C, Radi O, Veggiotti P, Mastronuzzi A, Acquaviva A, D'Ambrosio A, Locatelli F, Danesino C. 2009. Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. Br J Haematol 147: 706-709.
5. Jovanovic B, Krockel D, Linden D, Nilsson B, Egyhazi S, Hansson J. 2008. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol 128: 2696-2704.
6. Kobayashi T, Aoki Y, Niihori T, Cave H, Verloes A, Okamoto N, Kawame H, Fujiwara I, Takada F, Ohata T, Sakazume S, Ando T, Nakagawa N, Lapunzina P, Meneses AG, Gillessen-Kaesbach G, Wieczorek D, Kurosawa K, Mizuno S, Ohashi H, David A, Philip N, Guliyeva A, Narumi Y, Kure S, Tsuchiya S, Matsubara Y. 2010. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: Dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat 31: 284-294.
7. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B, Dicker F, Schnittger S, Dugas M, Kern W, Haferlach C, Haferlach T. 2010. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 28: 3858-3865.
8. Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K. 2011. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood 117: 2022-2032.
9. Narumi Y, Aoki Y, Niihori T, Sakurai M, Cave H, Verloes A, Nishio K, Ohashi H, Kurosawa K, Okamoto N, Kawame H, Mizuno S, Kondoh T, Addor MC, Coeslier-Dieux A, Vincent-Delorme C, Tabayashi K, Aoki M, Kobayashi T, Guliyeva A, Kure S, Matsubara Y. 2008. Clinical manifestations in patients with SOS1 mutations range from Noonan syndrome to CFC syndrome. J Hum Genet 53: 834-841.
10. Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, Aoki Y, Matsubara Y, Arveiler B, Lacombe D, Pasmant E, Parfait B, Baumann C, Heron D, Sigaudy S, Toutain A, Rio M, Goldenberg A, Leheup B, Verloes A, Cave H. 2007. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: Genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet 44: 763-771.
11. Perez B, Kosmider O, Cassinat B, Renneville A, Lachenaud J, Kaltenbach S, Bertrand Y, Baruchel A, Chomienne C, Fontenay M, Preudhomme C, Cave H. 2010. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Br J Haematol 151: 460-468.
12. Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, Lambertenghi Deliliers G, Beran M, Onida F. 2010. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 16: 2246-2256.
13. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA. 2010. Noonan syndrome: Clinical features, diagnosis, and management guidelines. Pediatrics 126: 746-759.
14. Runtuwene V, van Eekelen M, Overvoorde J, Rehmann H, Yntema HG, Nillesen WM, van Haeringen A, van der Burgt I, Burgering B, den Hertog J. 2011. Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects. Dis Model Mech 4: 393-399.
15. Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, Scioletti AP, Esposito G, Cordeddu V, Lepri F, Petrangeli V, Dentici ML, Mancini GM, Selicorni A, Rossi C, Mazzanti L, Marino B, Ferrero GB, Silengo MC, Memo L, Stanzial F, Faravelli F, Stuppia L, Puxeddu E, Gelb BD, Dallapiccola B, Tartaglia M. 2009. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrum. Hum Mutat 30: 695-702.
16. Tartaglia M, Gelb BD, Zenker M. 2011. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab 25: 161-179.
17. Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, Heinrich MC, Gattermann N, Gilliland DG, Druker BJ, Loriaux MM. 2009. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood 113: 1749-1755.
18. van der Burgt I, Berends E, Lommen E, van Beersum S, Hamel B, Mariman E. 1994. Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am J Med Genet 53: 187-191.
19. Wang J, Liu Y, Li Z, Wang Z, Tan LX, Ryu MJ, Meline B, Du J, Young KH, Ranheim E, Chang Q, Zhang J. 2011. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. Blood 118: 368-379.
20. Zenker M. 2011. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors. Curr Opin Pediatr 23: 443-451.